Thrombosis and bleeding in critical COVID-19 patients: two sides of the same coin

J Cardiovasc Med (Hagerstown). 2021 Sep 1;22(9):723-725. doi: 10.2459/JCM.0000000000001080.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • COVID-19* / blood
  • COVID-19* / diagnosis
  • COVID-19* / physiopathology
  • COVID-19* / therapy
  • Computed Tomography Angiography / methods
  • Fibrin Fibrinogen Degradation Products / analysis*
  • Hematoma* / complications
  • Hematoma* / diagnostic imaging
  • Hematoma* / therapy
  • Heparin* / administration & dosage
  • Heparin* / adverse effects
  • Humans
  • Hypoxia / etiology
  • Hypoxia / therapy
  • Lung* / diagnostic imaging
  • Lung* / pathology
  • Male
  • Middle Aged
  • Patient Care Management / methods
  • Patient Selection
  • Pulmonary Embolism* / complications
  • Pulmonary Embolism* / diagnostic imaging
  • Pulmonary Embolism* / etiology
  • Pulmonary Embolism* / therapy
  • Risk Adjustment / methods
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Anticoagulants
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • Heparin